Drug Profile
AKS 130
Alternative Names: AKS 130; Insulin long-acting - Akston BiosciencesLatest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Akston Biosciences
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Breast cancer
- No development reported Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 07 Dec 2021 Preclinical trials in Breast cancer in USA (Parenteral)
- 28 Sep 2021 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA (Parenteral, Injection)
- 28 Sep 2021 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (Parenteral, Injection)